Quote Request
ROR1 Inhibitor Development for Pancreatic Cancer
The development of ROR1 inhibitors has helped to tailor treatments to the genetic and molecular characteristics of individual tumors. Alfa Cytology's innovative solutions are designed to support the development of ROR1 inhibitors for pancreatic cancer by addressing all phases of the drug development process, providing expertise and resources to facilitate the translation of research results into potential therapeutic agents.
Overview of ROR1
ROR1 (Receptor tyrosine kinase-like orphan receptor 1) is a type I tyrosine-protein kinase transmembrane receptor, encoded by the ROR1 gene located on chromosome 1p31.3. ROR1 is involved in the regulation of embryonic development, cell survival, and differentiation. It plays a significant role in the non-canonical Wnt signaling pathway, where it interacts with Wnt5a to activate downstream signaling cascades such as the PI3K/AKT pathway. This signaling is critical for maintaining cellular homeostasis and promoting oncogenic processes in various cancers.
Fig. 1 Targeting ROR1 with small molecules and immunotherapy-a selection of agents. (Menck K, et al, 2021)
In the human body, ROR1 is typically expressed during embryogenesis and is minimally expressed in adult tissues, making it an attractive target for cancer therapies due to its re-expression in malignancies.
ROR1 Inhibitor Development for Pancreatic Cancer
ROR1 inhibitors work by specifically targeting ROR1 and disrupting the receptor's function, thereby impeding the downstream signaling pathways essential for pancreatic cancer cell growth and survival. The following pipeline drugs are being evaluated for their potential to inhibit ROR1 signaling pathways effectively, aimed to establish their safety, efficacy, and suitability as therapeutic options for patients with pancreatic cancer.
| ROR1 Inhibitor | Company | Target | Molecular Type | Phase |
|---|---|---|---|---|
| Cirmtuzumab | Oncternal Therapeutics | ROR1 | Monoclonal antibody | Phase I/II |
| VLS-101 | VelosBio | ROR1 | Antibody-drug conjugate | Phase I |
| KNG-101 | Kangpu Biopharmaceuticals | ROR1 | Small molecule inhibitor | Preclinical |
| NG-347 | Novartis | ROR1 | Small molecule inhibitor | Preclinical |
| ONC-211 | OncoMed Pharmaceuticals | ROR1 | Small molecule inhibitor | Preclinical |
Our Services
With expertise in preclinical research in pancreatic cancer, Alfa Cytology' is committed to providing optimal solutions for the development of ROR1 inhibitors for pancreatic cancer (PC), with the aim of delivering targeted and innovative therapies against pancreatic cancer at all levels of pathology and supporting the development of targeted therapies.
Molecule Types for ROR1 Inhibitor Development
Our ROR1 inhibitor development services target the key molecules and pathways associated with pancreatic cancer, developing targeted therapies across multi-molecular types.
Acts by binding to intracellular kinase structural domains, inhibiting their autophosphorylation and subsequent downstream signaling pathways.
Designed to specifically bind the extracellular structural domain of ROR1, block ligand-receptor interactions and trigger immune-mediated cytotoxicity.
Designed to bind to ROR1 and on both immune cells and cancer cells, thereby promoting targeted immune-mediated tumor cell destruction.
Genetically modify patient T cells to express a CAR targeting ROR1 to recognize and kill ROR1-expressing cancer cells.
Antibody-Drug Conjugates (ADCs)
Binding to ROR1 on the surface of cancer cells is internalized, releasing the cytotoxic agent directly into the tumor cells, leading to cell death.
Why Choose Us?
Tailored Solutions
We offer tailored research solutions to meet the specific needs of your project, ensuring precise and reliable results.
Advanced Technology
Our latest technologies can support high-throughput screening, detailed mechanistic studies, and preclinical evaluations.
Expertise
With years of dedicated experience, our team is well-versed in the complexities of pancreatic cancer biology.
Collaborative Approach
We work closely with our clients to understand their goals and provide expert guidance throughout the research process.
Targeting ROR1 represents a novel and promising approach in the treatment of pancreatic cancer. Leveraging cutting-edge technologies and scientific expertise, Alfa Cytology delivers innovative preclinical solutions for ROR1 inhibitor development. By disrupting key signaling pathways and biological processes, these inhibitors hold the potential to significantly improve therapeutic outcomes in pancreatic cancer, paving the way for future clinical advancements. In addition, we also provide more targeted therapy development for pancreatic cancer, such as natural killer cell modulator, apoptosis inhibitor, autophagy Inhibitor. For advice on how we can take your research forward, please contact us.
Reference
- Menck K, et al. The WNT/ROR pathway in cancer: from signaling to therapeutic intervention. Cells. 2021, 10(1): 142.
